Kendra Butner
Family · Higginsville, MONPI 1609958891
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $22,220 of the $34,834 with a category attached, or 63.8%. 40 manufacturers reported payments, led by Tandem Diabetes Care, Inc. at 59.2% of the total. 2025 is the largest year on record at $14,831, more than ten times the $1,449 reported in 2021. Among family clinicians in MO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 453 payments — averaging $76.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tandem Diabetes Care, Inc.$21K
- Lilly USA, LLC$3K
- Insulet Corporation$2K
- AbbVie$2K
- AstraZeneca$1K
- Amgen$923
- plus $5K from 34 others
What the payments were for
- Consulting fees$2,5007%
- Speaking & faculty fees$22,22064%
- Travel & lodging$1320%
- Food & beverage$9,81628%
- Education$1070%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tandem Diabetes Care, Inc. | 26 | $20,618 |
| Lilly USA, LLC | 53 | $3,432 |
| Insulet Corporation | 16 | $2,199 |
| AbbVie | 88 | $1,632 |
| AstraZeneca | 58 | $1,427 |
| Amgen | 27 | $923 |
| Dexcom, Inc. | 21 | $723 |
| Medtronic | 5 | $556 |
| Novo Nordisk | 34 | $543 |
| Abbott | 15 | $374 |
| Mannkind Corporation | 11 | $236 |
| Boehringer Ingelheim | 13 | $226 |
| Otsuka America Pharmaceutical, Inc. | 7 | $222 |
| Bayer | 11 | $196 |
| Merck | 10 | $169 |
| Teva Pharmaceuticals USA, Inc. | 3 | $145 |
| Amarin Pharma, Inc. | 8 | $123 |
| Axsome Therapeutics, Inc. | 2 | $114 |
| Antares Pharma, Inc. | 1 | $113 |
| Pfizer | 6 | $89 |
| Eisai Inc. | 2 | $78 |
| Biohaven Pharmaceutical Holding Company Ltd. | 4 | $73 |
| Sanofi-aventis U.S. LLC | 4 | $72 |
| Sequel Med Tech, LLC | 2 | $63 |
| Novartis | 3 | $61 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $48 |
| E.r. Squibb & Sons, L.L.C. | 2 | $47 |
| Vanda Pharmaceuticals Inc. | 3 | $45 |
| Exact Sciences | 2 | $36 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $32 |
| GSK | 2 | $31 |
| QOL Medical, LLC | 1 | $30 |
| Kyowa Kirin, Inc. | 1 | $28 |
| Xeris Pharmaceuticals, Inc. | 1 | $27 |
| Mylan Specialty L.p. | 1 | $25 |
| Lundbeck LLC | 1 | $22 |
| Neurelis, Inc. | 1 | $22 |
| Johnson & Johnson | 1 | $13 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Endogastric Solutions, Inc | 2 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- t:slim X2 Insulin Pump with Control-IQ$20,585
- Omnipod$2,000
- MOUNJARO$800
- Repatha$488
- MINIMED 780G$324
- AIRSUPRA$230
- DEXCOM G7 GSS (161)$149
- FARXIGA$126
- VRAYLAR$118
- TLANDO$113
- Austedo XR$112
- Otezla$107
- REXULTI$106
How this compares
$34,834 in reported general payments places this provider in the 95th percentile of 3,812 family providers in Missouri.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 103 | $125,040 |
| JardianceEmpagliflozin | 64 | $78,547 |
| FarxigaDapagliflozin Propanediol | 40 | $40,512 |
| TrulicityDulaglutide | 28 | $33,826 |
| AfrezzaInsulin Regular, Human | 18 | $32,494 |
| MounjaroTirzepatide | 24 | $25,594 |
| XareltoRivaroxaban | 19 | $20,192 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 42 | $19,986 |
| MyrbetriqMirabegron | 16 | $14,740 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 17 | $12,473 |
| JanuviaSitagliptin Phosphate | 16 | $11,414 |
| Tresiba Flextouch U-200Insulin Degludec | 18 | $10,014 |
| Repatha SureclickEvolocumab | 11 | $6,048 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $5,407 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 15 | $3,949 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $543 | $125,040103 claims |
| Boehringer IngelheimJardiance | $226 | $78,54764 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $3,432 | $59,42052 claims |
| AstraZenecaFarxiga | $1,427 | $40,51240 claims |
| Mannkind CorporationAfrezza | $236 | $32,49418 claims |
| Johnson & JohnsonXarelto | $13 | $20,19219 claims |
| GSKTrelegy Ellipta | $31 | $12,47317 claims |
| MerckJanuvia | $169 | $11,41416 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,812 family providers in Missouri.
Other family in Higginsville
- Shayla SandersKansas City$306K
- Tamera WolfLees Summit$215K
- Tiffany ArnoldFestus$177K
- Tiffany NelsonSedalia$164K
- Chelsey BeckerSaint Peters$104K
- Carey PattonDes Peres$94K
- Marcy MarkesColumbia$92K
- Laura HedigerSpringfield$71K
- Rebecca SeabaughSaint Louis$68K
- Jennifer GriggColumbia$46K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.